219 related articles for article (PubMed ID: 30526346)
21. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
Miyoshi Y; Ogawa O; Oyama Y
Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer.
Sabatier R; Nicolas E; Paciencia M; Jonville-Béra AP; Madroszyk A; Cecile M; Braticevic C; Duran S; Tassy L; Rouby F; Micallef J; Rousseau F
J Geriatr Oncol; 2018 Sep; 9(5):494-500. PubMed ID: 29530494
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
24. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
Kikuchi F; Saheki T; Imachi H; Kobayashi T; Fukunaga K; Ibata T; Sato S; Ban N; Lyu J; Japar S; Murao K
J Med Case Rep; 2021 Apr; 15(1):214. PubMed ID: 33892782
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
27. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
Matsumura K; Nagasawa K; Oshima Y; Kikuno S; Hayashi K; Nishimura A; Okubo M; Uruga H; Kishi K; Kobayashi T; Mori Y
J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
[TBL] [Abstract][Full Text] [Related]
29. Fulminant type 1 diabetes associated with Isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy.
Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Noso S; Ikegami H; Shiba T
Endocr J; 2019 Apr; 66(4):295-300. PubMed ID: 30814440
[TBL] [Abstract][Full Text] [Related]
30. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
31. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
Chae YK; Chiec L; Mohindra N; Gentzler R; Patel J; Giles F
Cancer Immunol Immunother; 2017 Jan; 66(1):25-32. PubMed ID: 27761609
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
33. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
Gettinger S; Horn L; Jackman D; Spigel D; Antonia S; Hellmann M; Powderly J; Heist R; Sequist LV; Smith DC; Leming P; Geese WJ; Yoon D; Li A; Brahmer J
J Clin Oncol; 2018 Jun; 36(17):1675-1684. PubMed ID: 29570421
[TBL] [Abstract][Full Text] [Related]
34. Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature.
Abdullah HMA; Elnair R; Khan UI; Omar M; Morey-Vargas OL
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31451458
[TBL] [Abstract][Full Text] [Related]
35. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report.
Kurihara S; Oikawa Y; Nakajima R; Satomura A; Tanaka R; Kagamu H; Shimada A
J Diabetes Investig; 2020 Jul; 11(4):1006-1009. PubMed ID: 31926048
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Kotwal A; Haddox C; Block M; Kudva YC
BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
[TBL] [Abstract][Full Text] [Related]
38. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
Jehl A; Cugnet-Anceau C; Vigouroux C; Legeay AL; Dalle S; Harou O; Marchand L; Lascols O; Caussy C; Thivolet C; Laville M; Disse E
Diabetes Care; 2019 Oct; 42(10):2008-2010. PubMed ID: 31434650
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring.
Tassone F; Colantonio I; Gamarra E; Gianotti L; Baffoni C; Magro G; Borretta G
Acta Diabetol; 2019 Apr; 56(4):489-490. PubMed ID: 30361845
[No Abstract] [Full Text] [Related]
40. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]